NO20053782L - Behandling av kreft med 2-deoksyglukose - Google Patents

Behandling av kreft med 2-deoksyglukose

Info

Publication number
NO20053782L
NO20053782L NO20053782A NO20053782A NO20053782L NO 20053782 L NO20053782 L NO 20053782L NO 20053782 A NO20053782 A NO 20053782A NO 20053782 A NO20053782 A NO 20053782A NO 20053782 L NO20053782 L NO 20053782L
Authority
NO
Norway
Prior art keywords
deoxyglucose
cancer
treatment
administered
administration
Prior art date
Application number
NO20053782A
Other languages
English (en)
Other versions
NO20053782D0 (no
Inventor
George Tidmarsh
Original Assignee
Treshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treshold Pharmaceuticals Inc filed Critical Treshold Pharmaceuticals Inc
Publication of NO20053782D0 publication Critical patent/NO20053782D0/no
Publication of NO20053782L publication Critical patent/NO20053782L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelsen 2-deoksyglukose kan benyttes for å behandle cancer og for å forbedre pasientutbyttet ved administrering i en terapeutisk effektiv dose og, eventuelt, koadministreres med andre anti-cancermedikamenter, eller i kombinasjon med kirurgisk reseksjon eller strålingsterapi.
NO20053782A 2003-01-10 2005-08-09 Behandling av kreft med 2-deoksyglukose NO20053782L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US43926603P 2003-01-10 2003-01-10
US45884603P 2003-03-28 2003-03-28
US45866503P 2003-03-28 2003-03-28
US46001203P 2003-04-02 2003-04-02
US49616303P 2003-08-18 2003-08-18
PCT/US2004/000530 WO2004062604A2 (en) 2003-01-10 2004-01-09 Treatment of cancer with 2-deoxyglucose

Publications (2)

Publication Number Publication Date
NO20053782D0 NO20053782D0 (no) 2005-08-09
NO20053782L true NO20053782L (no) 2005-09-27

Family

ID=32719656

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053782A NO20053782L (no) 2003-01-10 2005-08-09 Behandling av kreft med 2-deoksyglukose

Country Status (11)

Country Link
US (2) US6979675B2 (no)
EP (1) EP1587519A4 (no)
JP (1) JP2006515883A (no)
KR (1) KR20050098244A (no)
AU (1) AU2004204778B2 (no)
BR (1) BRPI0406667A (no)
CA (1) CA2513399A1 (no)
IL (1) IL169594A0 (no)
MX (1) MXPA05007382A (no)
NO (1) NO20053782L (no)
WO (1) WO2004062604A2 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795227B2 (en) 2004-06-17 2010-09-14 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
EP1205493A1 (en) * 2000-11-14 2002-05-15 ATOFINA Research Polymerisation catalyst systems and their preparation
US7666459B2 (en) * 2001-09-12 2010-02-23 The Procter & Gamble Company Pet food compositions
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
WO2004064734A2 (en) * 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
KR101226631B1 (ko) 2004-02-06 2013-01-28 쓰레솔드 파마슈티컬스, 인코포레이티드 항암 치료 방법
US20090252834A1 (en) * 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
WO2006024490A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Methods and compositions for the treatment of cell proliferation
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
WO2006050457A2 (en) * 2004-11-02 2006-05-11 Conforma Therapeutics Corporation Methods and compositions for treating chronic lymphocytic leukemia
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US7208611B2 (en) 2005-02-23 2007-04-24 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
EP1874407B1 (en) 2005-04-15 2015-09-09 Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
ATE512211T1 (de) 2005-05-31 2011-06-15 Iams Company Feline probiotische lactobacilli
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
JPWO2006137595A1 (ja) * 2005-06-24 2009-01-22 武田薬品工業株式会社 Ｈｅｒ２発現癌の予防・治療薬
US20070032383A1 (en) * 2005-07-27 2007-02-08 Newell M K Systems, methods, and compositions for modifying the metabolism of plants and of euucaryotic microbes
WO2007035755A2 (en) * 2005-09-19 2007-03-29 Duke University Methods of treating hematological malignancies
WO2007064448A2 (en) * 2005-11-28 2007-06-07 Ramot At Tel Aviv University, Ltd. Cancer treatment using fts and 2-deoxyglucose
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
US8242167B2 (en) * 2006-02-24 2012-08-14 University Of Miami Mannose derivatives for killing tumor cells
AU2007220777A1 (en) * 2006-02-24 2007-09-07 Board Of Regents, The University Of Texas System Hexose compounds to treat cancer
US9149489B2 (en) * 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2009108926A1 (en) * 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2007124700A2 (en) * 2006-05-03 2007-11-08 I.Q.A., A.S. Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
JP5358186B2 (ja) 2006-11-20 2013-12-04 国立大学法人 香川大学 デオキシケトヘキソース異性化酵素を用いるデオキシヘキソースおよびその誘導体の製造方法
WO2008076964A1 (en) * 2006-12-18 2008-06-26 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
EP2156188B1 (en) 2007-03-28 2021-05-05 University of Southern California Induction of differential stress resistance and uses thereof
US8865646B2 (en) * 2007-03-28 2014-10-21 University Of South California Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
RU2349271C2 (ru) * 2007-03-29 2009-03-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ лечения рака прямой кишки
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2008124691A1 (en) * 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
US20110091574A1 (en) * 2008-02-15 2011-04-21 Catholic Healthcare West Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox2 inhibitor
CA2716321A1 (en) 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2303282A4 (en) * 2008-05-23 2013-02-13 Univ Miami TREATMENT WITH CONTINUOUS LOW DOSED APPLICATION OF SUGAR ANALOGUE
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
ES2628180T3 (es) 2008-07-11 2017-08-02 Board Of Regents, The University Of Texas System Nuevos acetatos de 2-desoxi monosacáridos con actividad anticancerosa
WO2010008554A2 (en) * 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
WO2010019396A1 (en) * 2008-08-13 2010-02-18 Threshold Pharmaceuticals, Inc. Administration of glufosfamide for the treatment of cancer
US9492417B2 (en) * 2008-08-21 2016-11-15 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CA3024263A1 (en) * 2009-01-29 2010-08-05 Young Hee Ko Compositions and methods for the treatment of cancer
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
RU2561132C2 (ru) 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
WO2011050211A2 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
EP3095458B1 (en) * 2009-10-22 2018-07-25 Propanc Pty Ltd Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
CN102115483B (zh) * 2009-12-30 2014-12-17 苏州天人合生物技术有限公司 卤代双去氧糖衍生物及其制备方法与应用
GB2478556A (en) * 2010-03-09 2011-09-14 Myrovlytis Technology Ventures Ltd A composition for use in the treatment of Birt-Hogg-Dubô sydrome
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
DK2608796T3 (en) 2010-08-05 2019-03-18 Seattle Genetics Inc Inhibition of protein fucosylation in vivo using fucose analogues
BR112013009086A2 (pt) * 2010-10-13 2016-07-26 Mustafa Bilgin Ali Djamgoz tratamento de câncer/inibição de metástase
WO2012049439A1 (en) * 2010-10-13 2012-04-19 Imperial Innovations Limited Treatment of cancer/inhibition of metastasis
CA2824175A1 (en) * 2011-01-11 2012-07-19 The University Of Texas M.D. Anderson Cancer Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
WO2012123774A1 (en) * 2011-03-11 2012-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Glycolytic inhibitor with cytotoxic agent for use in the treatment of a cancer
US20120238511A1 (en) * 2011-03-14 2012-09-20 University Of Southern California 2-deoxy-d-glucose formulations for prevention or treatment of neurodegenerative diseases
SG194697A1 (en) 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013017282A1 (en) * 2011-08-02 2013-02-07 Roche Diagnostics Gmbh In vitro tumor metastasis model
KR101900478B1 (ko) * 2011-08-04 2018-09-20 한올바이오파마주식회사 암의 재발 또는 전이의 억제용 약제학적 조성물
NZ627096A (en) 2012-01-06 2017-02-24 Agios Pharmaceuticals Inc Triazinyl compounds and their methods of use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20160015725A1 (en) * 2012-02-14 2016-01-21 The Wistar Institute Of Anatomy And Biology Methods of controlling tumor bioenergetics networks
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
WO2014031875A1 (en) 2012-08-23 2014-02-27 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014072967A1 (en) * 2012-11-12 2014-05-15 Urifer Ltd Drug combination comprising a glycolysis inhibitor and a tyrosine kinase inhibitor
KR101419816B1 (ko) * 2013-01-30 2014-07-17 (주)제욱 상승적 치료 효과를 갖는 비소세포폐암의 예방 또는 치료용 조성물
EP3939595A1 (en) 2013-04-05 2022-01-19 Board of Regents, The University of Texas System Esters of 2-deoxy-monosaccharides with anti proliferative activity
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015108933A1 (en) 2014-01-14 2015-07-23 The Johns Hopkins University Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
WO2016065353A1 (en) * 2014-10-24 2016-04-28 University Of Miami Combination therapy with fenofibrate and 2-deoxyglucose or 2-deoxymannose
FI3307271T3 (fi) 2015-06-11 2023-10-17 Agios Pharmaceuticals Inc Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä
SG11201803088PA (en) 2015-10-15 2018-05-30 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
PT3362066T (pt) 2015-10-15 2021-11-16 Celgene Corp Terapia de combinação para tratar malignidades
WO2017079563A1 (en) 2015-11-06 2017-05-11 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
HK1259489A1 (zh) 2015-11-12 2019-11-29 普罗潘克股份有限公司 酶原组合物
CA3012398A1 (en) 2016-01-29 2017-08-03 Propanc Pty Ltd Cancer treatment based on chymotrypsinogen and trypsinogen
WO2017173360A2 (en) * 2016-03-31 2017-10-05 Stcube, Inc. Combination treatments directed toward programmed death ligand-1 (pd-l1) positive cancers
KR20200018634A (ko) 2017-06-28 2020-02-19 가부시키가이샤 센탄이료카이하츠 의약조성물 및 종양면역활성 촉진제
WO2019018683A1 (en) 2017-07-21 2019-01-24 Buck Institute For Research On Aging BETA-HYDROXYBUTYRATE AND BUTANEDIOL ENANTIOMERS AND METHODS OF USE THEREOF
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
WO2019222553A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
RU2707554C1 (ru) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Композиция, ингибирующая рост и выживаемость опухолевых клеток
US20230130134A1 (en) 2020-03-16 2023-04-27 Board Of Regents, The University Of Texas System Method of treating viral infections with hexose type monosaccharides and analogs thereof
WO2021211609A1 (en) * 2020-04-16 2021-10-21 Buck Institute For Research On Aging Treatment of viral pathologies with exogenous ketones
US12257273B2 (en) * 2020-12-14 2025-03-25 Trim Biotech, S.L. Compositions comprising bacteria for cancer immunotherapy
WO2023062516A1 (en) * 2021-10-11 2023-04-20 Exploration Invest Pte Ltd 2-deoxy-d-glucose for use in disease therapy
CN114617876B (zh) * 2022-01-28 2023-04-07 四川大学华西医院 一种抗肿瘤联合用药物
KR20240038394A (ko) 2022-09-16 2024-03-25 이화여자대학교 산학협력단 해당과정 억제제 및 미토콘드리아 기능 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS606630B2 (ja) 1977-09-07 1985-02-19 藤沢薬品工業株式会社 ２―デオキシ―ｄ―グルコースの製造法
US4315001A (en) 1979-08-17 1982-02-09 Blough Herbert A 2-Deoxy glucose as an antiviral agent against herpes simplex
US5185325A (en) 1988-06-23 1993-02-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic composition
EP0565785A1 (en) 1992-04-07 1993-10-20 Harry H. Leveen Use of glucose transport inhibitors for the treatment for acne
KR950009111B1 (ko) * 1992-09-08 1995-08-14 주식회사럭키 광택 조절용 수지의 제조방법
US5591429A (en) * 1993-07-26 1997-01-07 The United States Of America As Represented By The Secretary Of Agriculture Composition containing 2-deoxy-D-glucose and Candida saitoana and a method of use for the biological control of postharvest diseases
US5643883A (en) 1995-01-19 1997-07-01 Uab Research Foundation Glucose-6-phosphate uptake inhibitors and novel uses thereof
DE19524515A1 (de) 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US5652273A (en) 1995-11-30 1997-07-29 Henry; James Reduction of hair growth
US5565434A (en) 1996-02-23 1996-10-15 University Of Iowa Research Foundation Hexose and pentose prodrugs of ethacrynic acid
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US20020035071A1 (en) 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
GR1003713B (el) 1998-03-20 2001-11-07 Δεσοξυσακχαρα ως αντικαρκινικοι αναχαιτιστικοι παραγοντες.
US20030072814A1 (en) 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US6974664B2 (en) 2000-05-12 2005-12-13 The Board Of Trustees Of The Leland Stanford University Screening method for cancer therapeutics and stable antitumor drug
WO2002058741A2 (en) 2000-12-18 2002-08-01 Alex Wah Hin Yeung Treatment of cancer with positron-emitting radiopharmaceuticals
US6661410B2 (en) * 2001-09-07 2003-12-09 Microsoft Corporation Capacitive sensing and data input device power management

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795227B2 (en) 2004-06-17 2010-09-14 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders

Also Published As

Publication number Publication date
EP1587519A2 (en) 2005-10-26
KR20050098244A (ko) 2005-10-11
US20050245462A1 (en) 2005-11-03
EP1587519A4 (en) 2006-05-31
US20040167079A1 (en) 2004-08-26
JP2006515883A (ja) 2006-06-08
MXPA05007382A (es) 2005-11-23
WO2004062604A2 (en) 2004-07-29
IL169594A0 (en) 2007-07-04
WO2004062604A3 (en) 2005-05-26
NO20053782D0 (no) 2005-08-09
US6979675B2 (en) 2005-12-27
CA2513399A1 (en) 2004-07-29
AU2004204778A1 (en) 2004-07-29
BRPI0406667A (pt) 2005-12-20
AU2004204778B2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
NO20014842D0 (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
NO20060307L (no) Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
EA200500859A1 (ru) Хинолинилпирролопиразолы
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
NO20032027L (no) Effektive antitumorbehandlinger
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
CA2514227A1 (en) Combination therapy of zd6474 with 5-fu or/and cpt-11
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
DE602004016754D1 (de) Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
van derBoon New drug slows prostate-cancer progression
WO2007103828A3 (en) Fluorocytidine derivatives and cox-2 inhibitors for the treatment of cancer
MX2026000880A (es) Sales, cocristales, composiciones farmaceuticas de los mismos, y metodos de tratamiento que implican los mismos
RU2007106415A (ru) Способ лечения тяжелой формы вульгарных угрей

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application